The impact of the COVID-19 pandemic on the incidence of invasive pneumococcal disease in the Czech Republic and whole genome sequencing analysis of Streptococcus pneumoniae serotypes 3 and 19A from 2018–2024

Česká verze

Authors: J. Kozáková ¹ ; S. Vohrnová ^1,2 ; M. Honskus ^1,2 ; P. Křížová ¹ ; M. Malý ³
Authors place of work: Národní referenční laboratoř pro streptokokové nákazy, Centrum epidemiologie a mikrobiologie, Státní zdravotní ústav, Praha ¹; 3. lékařská fakulta Univerzity Karlovy, Praha ²; Oddělení biostatistiky, Státní zdravotní ústav, Praha ³
Published in the journal: Epidemiol. Mikrobiol. Imunol. 75, 2026, č. 2, s. 47-65
Category: Původní práce
doi: https://doi.org/10.61568/emi/11-6717/20260323/143208

Summary

Aim: To describe in detail changes in the incidence of invasive pneumococcal disease in the Czech Republic during and after the COVID-19 pandemic. Another objective is molecular analysis of S. pneumoniae isolates of serotypes 3 and 19A recovered in the Czech Republic between 2018 and 2024. Material and methods: Data on the incidence of invasive pneumococcal disease and S. pneumoniae serotypes were obtained from the invasive pneumococcal disease surveillance program in the Czech Republic. S. pneumoniae isolates of serotypes 3 (63) and 19A (66) from 2018–2024 were subjected to whole genome sequencing (WGS) to characterize the GPSCs (Global Pneumococcal Sequence Clusters) and STs (sequence types) and place them in a global context. Results: During the COVID-19 pandemic, a significant decline was observed in the incidence of influenza in the Czech Republic. Following the pandemic, the incidence of influenza rose again to significantly higher levels than before the pandemic. Compared to the 2018–2019 period, the incidence of certain serotypes increased in 2023–2024, including vaccine serotypes 3, 4, 14, and 15B, while the incidence of serotypes 8, 12F, and 15A, among others, decreased. Whole genome sequencing analysis demonstrated the dominance of GPSC12 ST-180 among serotype 3 isolates throughout the study period. Among serotype 19A isolates, GPSC4 prevailed, particularly ST-416. Conclusions: The COVID-19 pandemic has demonstrated how rapidly the epidemiological situation of invasive pneumococcal disease can change and that continuous, systematic surveillance of invasive pneumococcal disease is necessary. The best prevention against IPD is vaccination, primarily with higher valency pneumococcal conjugate vaccines.

Keywords:

vaccination – Streptococcus pneumoniae – serotype – whole genome sequencing – invasive pneumococcal disease – COVID-19 pandemic – pneumococcal conjugate vaccines

Zdroje

1. Greenberg D, Broides A, Blancovich I et al. Relative importance of nasopharyngeal versus oropharyngeal sampling for isolation of Streptococcus pneumoniae and Haemophilus influenzae from healthy and sick individuals varies with age. J Clin Microbiol. 2004;42(10):4604-9. DOI: 10.1128/JCM.42.10.4604 -⁠ 4609.2004. PMID: 15472316; PMCID: PMC522367.

2. GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis., 2025,S1473–3099(25)00689–9. DOI: 10.1016/S1473 -⁠ 3099(25)00689-9. Epub ahead of print. PMID: 41412141.

3. GBD 2019 Meningitis Antimicrobial Resistance Collaborators. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2023;22(8):685–711. DOI: 10.1016/S1474-4422(23)00195-3. PMID: 37479374; PMCID: PMC10356620.

4. Invazivní pneumokoková onemocnění v České republice. Zprávy Centra epidemiologie a mikrobiologie. Dostupné na www: https://szu.gov.cz/temata-zdravi-a-bezpecnosti/a-z-infekce/s/ streptokokova-infekce/invazivni-pneumokokova-onemocneni -⁠ -v-ceske-republice/ (4.12.2025)

5. Lim RH, Chow A, Ho HJ. Decline in pneumococcal disease incidence in the time of COVID-19 in Singapore. J Infect., 2020;81(6):e19–e21. DOI: 10.1016/j.jinf.2020.08.020. Epub 2020 Aug 15. PMID: 32810519; PMCID: PMC7428708.

6. Juan HC, Chao CM, Lai CC et al. Decline in invasive pneumococcal disease during COVID-19 pandemic in Taiwan. J Infect. 2021;82(2):282–327. DOI: 10.1016/j.jinf.2020.09.018. Epub 2020 Sep 19. PMID: 32956735; PMCID: PMC7501066.

7. Teng JLL, Fok KMN, Lin KPK et al. Substantial Decline in Invasive Pneumococcal Disease During Coronavirus Disease 2019 Pandemic in Hong Kong. Clin Infect Dis., 2022;74(2):335 –⁠ 338. DOI: 10.1093/cid/ciab382. PMID: 33907808; PMCID: PMC8135303.

8. Steens A, Knol MJ, Freudenburg-de Graaf W et al. Pathogenand Type-Specific Changes in Invasive Bacterial Disease Epidemiology during the First Year of the COVID-19 Pandemic in The Netherlands. Microorganisms., 2022;10(5):972. DOI: 10.3390/microorganisms10050972. PMID: 35630415; PMCID: PMC9143569.

9. Clark SA, Campbell H, Ribeiro S et al. Epidemiological and strain characteristics of invasive meningococcal disease prior to, during and after COVID-19 pandemic restrictions in England. J Infect., 2023;87(5):385–391. DOI: 10.1016/j.jinf.2023.09.002. Epub 2023 Sep 7. PMID: 37689395.

10. Liechti FD, Bijlsma MW, Brouwer MC et al. Impact of the COVID-19 pandemic on incidence and serotype distribution of pneumococcal meningitis -⁠ A prospective, nationwide cohort study from the Netherlands. J Infect., 2024;88(1):65–67. DOI: 10.1016/j.jinf.2023.11.002. Epub 2023 Nov 9. PMID: 37949362.

11. Cuypers L, Dambre C, Desmet S. Exceptional high number of IPD cases in winter season 2024–2025 in Belgium in concomitance with rise in vaccine serotypes. Vaccine. 2025;64 : 127763. DOI: 10.1016/j.vaccine.2025.127763. Epub 2025 Sep 17. PMID: 40966978.

12. Vyhláška č. 389/2023 Sb., vyhláška o systému epidemiologické bdělosti pro vybraná infekční onemocnění, kterou se mění vyhláška č. 473/2008 Sb. A vyhláška č. 275/2010 Sb. Příloha č. 21 Systém epidemiologické bdělosti invazivních pneumokokových nebo streptokokových onemocnění. Dostupné na www: https://www.e-sbirka.cz/sb/2023/389/2024-11-15?zalozka=text (4.12.2025).

13. Metodický návod –⁠ Systém epidemiologické bdělosti invazivních pneumokokových onemocnění. Věstník Ministerstva zdravotnictví 2008. Dostupné na www: https://mzd.gov.cz/wp-content/uploads/wepub/1992/6150/V%C4%9Bstn%C3%ADk%20 02%202008.pdf (4.12.2025).

14. Case definitions for each infectious disease covered by EU surveillance, as published in the Official Journal of the European Union (Commission Implementing Decision (EU) 2018/945). Available on https://www.ecdc.europa.eu/en/all-topics/eu-case-definitions (4.12.2025).

15. Vacková Z, Klímová M, Kozáková J. Nová metoda a schéma typizace Streptococcus pneumoniae. Epidemiol Mikrobiol Imunol, 2013; 62 : 50–58.

16. Vacková Z, Lžičařová D, Stock NK et al. Detekce DNA Neisseria meningitidis, Haemophilus influenzae a Streptococcus pneumoniae v klinickém materiálu metodou real-time PCR. Epidemiol Mikrobiol Imunol., 2015;64(4):222–230. PMID: 26795226.

17. Kozáková J, Honskus M, Okonji Z. Implementace a využití metody sekvenace celého genomu (WGS) v surveillance invazivního pneumokokového onemocnění, Česká republika, 2017–2019. Epidemiol Mikrobiol Imunol., 2020, 69(3):134–141. ISSN 1210 -⁠ 7913.

18. Ewels P, Magnusson M, Lundin S et al. MultiQC: summarize analysis results for multiple tools and samples in a single report. Bioinformatics. 2016 Oct 1;32(19):3047–3048. doi: 10.1093/bioinformatics/btw354. Epub 2016 Jun 16. PMID: 27312411; PMCID: PMC5039924.

19. Hung HCH, Kumar N, Dyster V et al. GPS Pipeline: portable, scalable genomic pipeline for Streptococcus pneumoniae surveillance from Global Pneumococcal Sequencing Project. Nat Commun., 2025; 16 : 8345. Available on: https://doi. org/10.1038/s41467-025-64018-5.

20. Epping L, van Tonder AJ, Gladstone RA et al. SeroBA: rapid high-throughput serotyping of Streptococcus pneumoniae from whole genome sequence data. Microb Genom. 2018;4(7):e000186. DOI: 10.1099/mgen.0.000186. Epub 2018 Jun 15. Erratum in: Microb Genom. 2018 Aug;4(8). DOI: 10.1099/ mgen.0.000204. PMID: 29870330; PMCID: PMC6113868.

21. Gladstone RA, Lo SW, Lees JA et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine. 2019;43 : 338–346. DOI: 10.1016/j.ebiom.2019.04.021. Epub 2019 Apr 16. PMID: 31003929; PMCID: PMC6557916.

22. Lees JA, Harris SR, Tonkin-Hill G et al. Fast and flexible bacterial genomic epidemiology with PopPUNK. Genome Res. 2019;29(2):304–316. DOI: 10.1101/gr.241455.118. Epub 2019 Jan 24. PMID: 30679308; PMCID: PMC6360808.

23. Jolley KA, Bray JE, Maiden MCJ. Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications. Wellcome Open Res, 2018;3 : 124. DOI: 10.12688/wellcomeopenres.14826.1.

24. Maiden MCJ, Bygraves JA, Feil E et al. Multilocus sequence typing: A portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci U S A, 1998;95(6):3140–3145. DOI: 10.1073/pnas.95.6.3140.

25. Enright MC, Spratt BG. A multilocus sequence typing scheme for Streptococcus pneumoniae: identification of clones associated with serious invasive disease. Microbiology, 1998;144(11):3049 –⁠ 3060. DOI: 10.1099/00221287-144-11-3049.

26. Jolley KA, Chan MS, Maiden MC. MlstdbNet –⁠ distributed multi -⁠ -locus sequence typing (MLST) databases. BMC Bioinformatics, 2004; 5 : 86. DOI: 10.1186/1471-2105-5-86. PMID: 15230973.

27. Jolley KA, Bliss CM, Bennett JS et al. Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. Microbiology, 2012;158(4):1005–1015. DOI: 10.1099/mic.0.055459-0.

28. Jolley KA, Maiden MC. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics, 2010;11 : 595. DOI: 10.1186/1471-2105-11-595.

29. Jansen van Rensburg MJ, Berger DJ, Yassine I et al. Development of the Pneumococcal Genome Library, a core genome multilocus sequence typing scheme, and a taxonomic life identification number barcoding system to investigate and define pneumococcal population structure. Microb Genom., 2024;10(8):001280. DOI: 10.1099/mgen.0.001280. PMID: 39137139; PMCID: PMC11321556.

30. Huson DH. SplitsTree: analyzing and visualizing evolutionary data. Bioinformatics, 1998;14(1):68–73. DOI: 10.1093/bioinformatics/14.1.68.

31. Hilbe JM. Modeling count data. Cambridge University Press, New York, 2014.

32. Khongyot T, Moriyasu T. Invasive Pneumococcal Disease diminish during the onset of COVID-19 in Japan between 2019 and 2022. Int J Infect Dis. 2022;122 : 307–309. DOI: 10.1016/j.ijid.2022.05.064. Epub 2022 Jun 6. PMID: 35671951; PMCID: PMC9167682.

33. Prasad N, Rhodes J, Deng L et al. Changes in the Incidence of Invasive Bacterial Disease During the COVID-19 Pandemic in the United States, 2014–2020. J Infect Dis., 2023;227(7):907–916. DOI: 10.1093/infdis/jiad028. PMID: 36723871; PMCID: PMC10961849.

34. Kastrin T, Mioč V, Mahnič A et al. Impact of the COVID-19 Pandemic on Community Consumption of Antibiotics for Systemic Use and Resistance of Invasive Streptococcus pneumoniae in Slovenia. Antibiotics (Basel). 2023;12(6):945. DOI: 10.3390/antibiotics12060945. PMID: 37370264; PMCID: PMC10295396.

35. Almeida SCG, Lemos APS, Bierrenbach AL et al. Serotype Distribution and Antimicrobial Susceptibility Pattern of Streptococcus pneumoniae in COVID-19 Pandemic Era in Brazil. Microorganisms, 2024;12(2):401. DOI: 10.3390/microorganisms12020401. PMID: 38399805; PMCID: PMC10893029.

36. Brueggemann AB, Jansen van Rensburg MJ, Shaw D et al. Changes in the incidence of invasive disease due to Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis during the COVID-19 pandemic in 26 countries and territories in the Invasive Respiratory Infection Surveillance Initiative: a prospective analysis of surveillance data. Lancet Digit Health, 2021;3(6):e360–e370. DOI: 10.1016/S2589-7500(21)00077 -⁠ 7. Erratum in: Lancet Digit Health. 2021 Jul;3(7):e413. DOI: 10.1016/S2589-7500(21)00103-5. PMID: 34045002; PMCID: PMC8166576.

37. Shaw D, Abad R, Amin-Chowdhury Z et al. Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium. Lancet Digit Health, 2023;5(9):e582–e593. doi: 10.1016/S2589-7500(23)00108-5. Epub 2023 Jul 27. PMID: 37516557; PMCID: PMC10914672.

38. Principi N, Autore G, Ramundo G et al. Epidemiology of Respiratory Infections during the COVID-19 Pandemic. Viruses, 2023;15(5):1160. DOI: 10.3390/v15051160. PMID: 37243246; PMCID: PMC10224029.

39. Wolter N, Tempia S, Cohen C et al. High nasopharyngeal pneumococcal density, increased by viral coinfection, is associated with invasive pneumococcal pneumonia. J Infect Dis., 2014;210(10):1649–1657. DOI: 10.1093/infdis/jiu326. Epub 2014 Jun 6. PMID: 24907383.

40. Berry I, Tuite AR, Salomon A et al. Association of Influenza Activity and Environmental Conditions With the Risk of Invasive Pneumococcal Disease. JAMA Netw Open., 2020;3(7):e2010167. DOI: 10.1001/jamanetworkopen.2020.10167. PMID: 32658286; PMCID: PMC7358913.

41. Choe YJ, Park S, Michelow IC. Co-seasonality and co-detection of respiratory viruses and bacteraemia in children: a retrospective analysis. Clin Microbiol Infect., 2020;26(12):1690.e5-1690.e8. doi: 10.1016/j.cmi.2020.09.006. Epub 2020 Sep 10. PMID: 32919073; PMCID: PMC7481115.

42. Danino D, Ben-Shimol S, van der Beek BA et al. Decline in Pneumococcal Disease in Young Children During the Coronavirus Disease 2019 (COVID-19) Pandemic in Israel Associated With Suppression of Seasonal Respiratory Viruses, Despite Persistent Pneumococcal Carriage: A Prospective Cohort Study. Clin Infect Dis., 2022;75(1):e1154–e1164. DOI: 10.1093/cid/ciab1014. PMID: 34904635; PMCID: PMC8754767.

43. Bertran M, Amin-Chowdhury Z, Sheppard CL et al. Increased Incidence of Invasive Pneumococcal Disease among Children after COVID-19 Pandemic, England. Emerg Infect Dis., 2022;28(8):1669–1672. DOI: 10.3201/eid2808.220304. PMID: 35876698; PMCID: PMC9328924.

44. Perniciaro S, van der Linden M, Weinberger DM. Reemergence of Invasive Pneumococcal Disease in Germany During the Spring and Summer of 2021. Clin Infect Dis., 2022;75(7):1149–1153. DOI: 10.1093/cid/ciac100. PMID: 35136983; PMCID: PMC9383454.

45. Shaw D, Abad R, Almeida SCG et al. Quantifying the impact of the COVID-19 pandemic on invasive bacterial diseases across 27 countries and territories: prospective surveillance by the IRIS Consortium. [preprint], DOI: https://doi.org/10.1101/2025.07.10 .25331197.

46. Cohen R, Ashman M, Taha MK et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now., 2021;51(5):418–423. doi: 10.1016/j.idnow.2021.05.004. Epub 2021 May 12. PMID: 33991720; PMCID: PMC8114587.

47. Harris RC, Chen Y, Côte P et al. Impact of COVID-19 on routine immunisation in South-East Asia and Western Pacific: Disruptions and solutions. Lancet Reg Health West Pac., 2021;10 : 100140. DOI: 10.1016/j.lanwpc.2021.100140. Epub 2021 Apr 21. PMID: 33899040; PMCID: PMC8057868.

48. Chandir S, Siddiqi DA. Inequalities in COVID-19 disruption of routine immunisations and returning to pre-COVID immunisation rates. Lancet Reg Health West Pac. 2021;10 : 100156. DOI: 10.1016/j.lanwpc.2021.100156. Epub 2021 Apr 27. PMID: 33937886; PMCID: PMC8076654.

49. McQuaid F, Mulholland R, Sangpang Rai Y et al. Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data. PLoS Med. 2022;19(2):e1003916. DOI: 10.1371/ journal.pmed.1003916. PMID: 35192611; PMCID: PMC8863286.

50. Ben-Shimol S, Greenberg D, Givon-Lavi N et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine, 2014;32(27):3452–3459. DOI: 10.1016/j.vaccine.2014.03.065.

Epub 2014 Mar 30. PMID: 24690148.

51. van der Linden M, Falkenhorst G, Perniciaro S et al. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One, 2015;10(7):e0131494. DOI: 10.1371/journal.pone.0131494. PMID: 26132078; PMCID: PMC4488910.

52. Ladhani SN, Collins S, Djennad A et al. Rapid increase in non-vaccine serotypes causing invasive pneumococcal disease in England and Wales, 2000–17: a prospective national observational cohort study. Lancet Infect Dis. 2018;18(4):441–451. DOI: 10.1016/S1473-3099(18)30052-5. Epub 2018 Jan 26. Erratum in: Lancet Infect Dis. 2018 Apr;18(4):376. DOI: 10.1016/S1473-3099(18)30074-4. PMID: 29395999.

53. Ciruela P, Izquierdo C, Broner S et al. The changing epidemiology of invasive pneumococcal disease after PCV13 vaccination in a country with intermediate vaccination coverage. Vaccine, 2018;36(50):7744–7752. DOI: 10.1016/j.vaccine.2018.05.026. Epub 2018 Jun 30. PMID: 30473132.

54. Wijayasri S, Hillier K, Lim GH et al. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007–2017. PLoS One. 2019;14(12):e0226353. DOI: 10.1371/journal.pone.0226353. PMID: 31834926; PMCID: PMC6910703

55. Maeda H, Morimoto K. Global distribution and characteristics of pneumococcal serotypes in adults. Hum Vaccin Immunother., 2025;21(1):2469424. DOI: 10.1080/21645515.2025.2469424. Epub 2025 Feb 27. PMID: 40015240; PMCID: PMC11869777.

56. Bennett JC, Deloria Knoll M, Kagucia EW et al. Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis. Lancet Infect Dis., 2025;25(4):457–470. doi: 10.1016/S1473-3099(24)00665-0. Epub 2024 Dec 17. Erratum in: Lancet Infect Dis. 2025 Mar;25(3):e137. DOI: 10.1016/S1473-3099(25)00032-5. PMID: 39706204; PMCID: PMC11947069.

57. Albrich WC, Just N, Kahlert C et al. Serotype epidemiology and case-fatality risk of invasive pneumococcal disease: a nationwide population study from Switzerland, 2012–2022. Emerg Microbes Infect., 2025;14(1):2488189. DOI: 10.1080/22221751.2025.2488189. Epub 2025 Apr 24. PMID: 40167153; PMCID: PMC12024505.

58. Higgs C, Kumar LS, Stevens K et al. Population structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in Victoria, Australia. Microb Genom. 2023;9(7):mgen001070. DOI: 10.1099/mgen.0.001070. PMID: 37471116; PMCID: PMC10438814.

59. Eldholm V, Osnes MN, Bjørnstad ML et al. A genome-based survey of invasive pneumococci in Norway over four decades reveals lineage-specific responses to vaccination. Genome Med. 2024;16(1):123. DOI: 10.1186/s13073-024-01396-3. PMID: 39456053; PMCID: PMC11515192.

60. D‘Aeth JC, Bertran M, Abdullahi F et al. Whole-genome sequencing, strain composition, and predicted antimicrobial resistance of Streptococcus pneumoniae causing invasive disease in England in 2017–20: a prospective national surveillance study. Lancet Microbe. 2025;6(7):101102. doi: 10.1016/j.lanmic.2025.101102. Epub 2025 May 24. PMID: 40425021.

61. Slotved HC, Johannesen TB, Stegger M et al. Global pneumococcal sequence cluster lineage for invasive pneumococcal isolates in Denmark from summer 2019 to 2023. Sci Rep., 2025;15(1):24566. DOI: 10.1038/s41598-025-10149-0. PMID: 40628904; PMCID: PMC12238554.

62. Desmet S, Theeten H, Laenen L et al. Characterization of Emerging Serotype 19A Pneumococcal Strains in Invasive Disease and Carriage, Belgium. Emerg Infect Dis. 2022;28(8):1606–1614. DOI: 10.3201/eid2808.212440. PMID: 35876488; PMCID: PMC9328928.

63. Corcoran M, Mereckiene J, Cotter S et al. Using genomics to examine the persistence of Streptococcus pneumoniae serotype 19A in Ireland and the emergence of a sub-clade associated with vaccine failures. Vaccine, 2021;39(35):5064–5073. DOI: 10.1016/j.vaccine.2021.06.017. Epub 2021 Jul 21. PMID: 34301430.

64. Kozáková J, Okonji Z, Honskus M. Populační analýza Streptococcus pneumoniae sérotypu 19A metodou sekvenace celého genomu v České republice a Evropě po jeho zařazení do pneumokokové konjugované vakcíny. Epidemiol Mikrobiol Imunol., 2021;70(2):110–117. PMID: 34412487.

65. Žemličková H, Mališová L, Španělová P et al. Molecular characterization of serogroup 19 Streptococcus pneumoniae in the Czech Republic in the post-vaccine era. J Med Microbiol. 2018;67(7):1003–1011. DOI: 10.1099/jmm.0.000765. Erratum in: J Med Microbiol. 2018 Aug;67(8):1202. doi: 10.1099/ jmm.0.000795. PMID: 29856703; PMCID: PMC6152367.

66. Gladstone RA, Lo SW, Lees JA et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine, 2019, 43 : 338–346. DOI: 10.1016/j.ebiom.2019.04.021. Epub 2019 Apr 16. PMID: 31003929; PMCID: PMC6557916.